A loss of balance between G-protein activation and deactivation has been implicated in the initiation of melanomas, and non-canonical Wnt signaling via the Wnt5A/Frizzled (FZD) pathway has been shown to be critical for the switch to an invasive phenotype. Daple [CCDC88C gene], a cytosolic guanine nucleotide exchange factor (GEF) which enhances non-canonical Wnt5A/FZD signaling via activation of trimeric G protein, Gαi has been shown to serve opposing roles--as an inducer of EMT and invasiveness and a potent tumor suppressor --via two isoforms, V1 (full-length) and V2, respectively. Here we report that the relative abundance of these isoforms in the peripheral circulation, presumably largely from circulating tumor cells (CTCs), is a prognostic marker of cutaneous melanomas. Expression of V1 is increased in both the early and late clinical stages (p<0.001, p=0.002, respectively); V2 is decreased exclusively in the late clinical stage (p=0.011). The two isoforms have opposing prognostic effects: high expression of V2 increases progression-free survival (PFS; p = 0.02), whereas high expression of V1 decreases PFS (p=0.013). Furthermore, these effects are additive, in that melanoma patients with a low V2-high V1 signature carry the highest risk of metastatic disease. We conclude that detection of Daple transcripts in the peripheral blood (i.e., liquid biopsies) of patients with melanoma may serve as a prognostic marker and an effective strategy for noninvasive long-term follow-up of patients with melanoma.
Introduction:
Melanoma is a highly malignant cancer and causes more deaths than other forms of skin cancer; as in most cancers, early detection and surgical intervention are imperative for a curative outcome. However, in the case of melanoma, even with 'curative' surgical resection , the risk of recurrence is never completely absent and late recurrences, even beyond 8 y, can occur at a frequency ranging from 0.41% to 25% across different studies, with 6.8% at 15 y and 11.3% at 25 y 1,2 . The late recurrence population is particularly interesting to study as it represents a group of patients exhibiting tumor dormancy, defined as a stage in cancer progression in which residual disease is present but remains asymptomatic 2 . Hence, early detection of patients in this clinical stage of melanoma is of paramount importance so that they can be offered adjuvant therapy.
Tumor dormancy is best studied by examining patients who demonstrate persistent circulating or disseminated tumor cells (CTC or DTC) after removal of all clinically evident disease 3 . In fact, metastatic melanoma was the first malignancy in which CTCs were detected 4 . More recently, the presence of circulating melanoma cells (CMCs) in the peripheral blood of patients with metastatic cutaneous melanoma has been identified by detecting mRNA transcripts of specific melanoma markers. Transcripts from one or more circulating melanoma cells (CMCs) in 10 ml of peripheral blood can be identified in 45% of all melanoma patients at varying disease stages (AJCC Stages I /II, III, and IV: 35%, 44%, and 86%, respectively) [5] [6] [7] [8] [9] . While the prognostic impact of the number of CMCs remains to be determined, the prognostic impact of detecting molecular markers from these CMCs in the peripheral blood of melanoma patients has been evaluated by multiple groups within the last decade. These studies are in general agreement that the detection of unique multi-panel biomarkers such as S100B, MAGE-3, p97, MUC-18, S100A4, MART1, HMB45, and tyrosinase, by real-time quantitative PCR (RT-PCR) in CMCs of melanoma patients can have a valuable prognostic utility, especially in patients with Stage II and III disease [10] [11] [12] [13] [14] . These studies demonstrate that molecular detection of CMCs may be valuable to detect early disease recurrence and to stratify patients for adjuvant therapy. However, given the heterogeneous nature of melanoma cells, no single marker or panel of markers appears to be sufficiently robust in predicting outcome.
Despite these insights, the identification of CMC-biomarkers with strong rationale and mechanistic insights and specifically within signaling pathways known to fuel melanoma metastasis, remains unexplored and unrealized. In this regard, several studies agree that activation of non-canonical Wnt signaling and inactivation of the canonical Wnt pathway is associated with metastatic features of melanoma and thus poor survival [15] [16] [17] .. Here we report the identification of Daple (CCDC88C), a cytoplasmic transducer of Wnt signals [18] [19] [20] , as a candidate marker for monitoring deregulated Wnt signaling during melanoma progression.
Daple links ligand-activated Frizzled receptors to Gi protein activation 18 . Such activation, on one hand antagonizes the canonical Wnt pathway and suppresses a neoplastic transformation and tumor growth. On the other hand, it enhances non-canonical Wnt pathway and Akt signals, triggering epithelial-mesenchymal transition (EMT) and tumor invasion 18 . Subsequent work unraveled that Daple-dependent modulation of Wnt signaling is triggered not just by Wnt ligands 18 , but also by growth factors (EGF) 20 and junctions-associated Cadherin-catenin complexes that trigger the PI3K-Akt pathway 19 . Perhaps as a consequence of such convergent signaling, ourselves and others have demonstrated Daple's role in fueling the metastatic progression of gastric 21 and colorectal cancers (CRCs) 18, 22 and its ability to serve as a prognostic marker in the CTCs of patients with metastatic CRCs 22, 23 . We hypothesized that detection of Daple transcripts in the peripheral blood of patients with melanoma may serve as a surrogate marker for deregulated Wnt signaling during melanoma progression. Our findings present evidence that tracking levels of its transcripts could serve as an effective strategy for non-invasive long-term follow-up of patients with melanoma.
Results and Discussion

Rationale for choosing Daple as a biomarker for metastatic progression of melanoma
We previously reported that the Disheveled-binding protein, Daple, is a guanine nucleotide exchange modulator (GEM) for heterotrimeric G proteins within the Wnt signaling cascade 18 .
Subsequent work revealed that the human Daple/CCDC88C gene is expressed as two functional isoforms: Daple-full length (V1) (2028aa) and Daple-V2 (552aa) 22 . These isoforms serve contrasting roles during cancer progression--while both isoforms cooperatively antagonize Wnt signaling and suppress tumor cell proliferation and growth via their GBA motif, only the full-length V1 isoform triggers EMT and invasion. In the colon, both isoforms collaboratively suppress tumor cell growth, and have an additive prognostic impact (worse outcome when both are suppressed). However, only Daple-V1 is increased in invasive tumor margins and in CTCs disseminated during CRCs progression. We next chose to study the role of Daple in melanoma, which, like colorectal cancers, is another cancer that is characterized by dysregulation of heterotrimeric G-protein as well as Wnt signaling; prior studies have implicated both pathways in the metastatic progression of melanomas 24, 25 . When we analyzed the RNA sequencing dataset from The Cancer Genome Atlas (TCGA) for dysregulation of Daple/CCDC88C expression (CNVs, deletions or mutations) and the frequently mutated heterotrimeric G-protein GNAQ 26 , we found that mutations have been identified in patients with cutaneous, but not uveal melanomas for Daple/CCDC88C. For GNAQ, on the other hand, although mutations have been identified in both cutaneous and uveal melanomas, these are predominantly found in uveal melanomas (Fig 1A-B ). Mutations found in Daple/CCDC88C included both missense and truncating mutations (Supplemental Fig S1-S2) . Notably, mutations in other heterotrimeric G-protein α -subunits (GNAI1, GNAI2, GNAI3, and GNAS) that are modulated by this family of GEMs (of which Daple is a member and CCDC88A/Girdin and NUCB1/2 are others) were only found in cutaneous melanomas (Fig 1B) . These findings, along with the observation that Daple/CCDC88C was indeed abundantly expressed in distant metastases to diverse organs or sites (Supplemental Fig S3) , led us to hypothesize that dysregulated signaling via Daple/CCDC88C in cutaneous melanomas may have a role in the progression to metastatic disease.
Transcripts of Daple-V1 (V1), but not Daple-V2, is increased in the peripheral circulation of patients with melanoma.
We recently showed that the expression of Daple full-length (henceforth, Daple-V1) was elevated in EpCAM-immuno-isolated CTCs of colorectal cancer patients, and that Daple promotes epithelial-to-mesenchymal transition (EMT) during progression 18, 22 . Expression of Daple-V2, on the other hand, was found to be decreased in primary CRC tumors 22 . Because Daple-V1 and -V2 are differentially expressed in CTCs of CRCs patients we first asked if this is also the case in patients with melanoma (see Table 1 for patient cohort characteristics).
Because detection of melanoma transcripts in the peripheral blood is a sensitive surrogate marker of melanoma CTCs 8, 27 , we analyzed the abundance of Daple transcripts in the peripheral blood of patients with melanoma (n = 205) and of healthy controls (n = 142) by qRT-PCR. We found that patients with melanoma have significantly elevated levels of Daple-V1 expression compared to normal healthy controls (p < 0.0001; Fig. 2A, B) . The same pattern of expression was observed as for the melanocyte marker and the metastasis-associated protein, S100A4 28 , which is a transcriptional target of the Wnt-β-Catenin pathway 29 and currently used as a marker to diagnose melanoma 30 . By contrast, no difference in Daple-V2 expression was observed between transcripts in peripheral blood of melanoma patients and the healthy controls (Fig 2A-B) . These findings indicate that transcripts of full length Daple-V1, but not V2 are selectively upregulated in patients with melanoma and suggest that high levels of Daple-V1 may contribute to melanoma progression.
Transcripts of Daple-V1 increase, but Daple-V2 decrease in the peripheral blood of patients during melanoma progression
To further dissect the patterns of expression of Daple-V1 and Daple-V2 relative to disease stage, we analyzed both isoforms in the peripheral circulation of patients with early stage (AJCC stages 0, I, II) vs. late stage (AJCC stages III, IV) melanomas. We found that Daple-V1 expression is significantly increased in both early (p < 0.001; Fig. 3A ) and late (p = 0.002; Fig.   3A ) stages compared to healthy controls. Expression of Daple-V2 is significantly lower in late stage melanoma compared to early stage disease and healthy controls (p = 0.008 and 0.003, respectively; Fig. 3B ); no significant differences were noted between healthy and early stage melanoma patients. Levels of expression of S100A4, the positive control we used in this study, was increased in both early (0, I, II) and late (III, IV) stages ( Fig. 3C ) compared to normal healthy controls (p < 0.001 and 0.01, respectively). The changes in Daple expression we observe relative to disease stage are consistent with the patterns of Daple-V1 vs. V2 expression in CRC stages; in both scenarios Daple-V1 increases but Daple-V2 decreases as the disease progresses from the early state to the late invasive stage and undergoes hematogenous dissemination. The change in these transcripts in peripheral blood may reflect the entrance of CTCs into the peripheral circulation 22 .
Elevated Daple-V1 and suppressed Daple-V2 transcripts in the peripheral circulation of patients with early stage melanoma carries an increased risk for distant metastasis.
Next, we asked if the levels of expression of Daple-V1 and Daple-V2 in the peripheral blood of early stage melanoma patients can correlate with the frequency of progression to metastatic disease. In 145 patients with early stage melanoma, who progressed to metastatic disease, we found that low expression of Daple-V2 was associated with a higher metastatic rate (14.44%) compared to high expression of Daple-V2 (1.82%; p = 0.0174; Fig. 4A ). This pattern was not seen in the case of Daple-V1; in fact, high expression of Daple-V1 tracked with higher metastatic rate (16.33%) compared to low expression of Daple-V1, although that trend did not reach significance (6.25%; p = 0.073; Fig. 4B ). When we compared the rates of metastatic progression between a group of patients with a high Daple-V1-low Daple-V2 signature and another group with low Daple-V1-high Daple-V2 signature, we found that the former has a much higher metastatic rate (36.36%) compared to the latter (3.57%; p = 0.006; Fig. 4C ). These findings suggest that an analysis that accounts for the levels of expression of both Daple isoforms could perform better in prognosticating outcome than each one alone, i.e., Daple-V1 and Daple-V2 may have an additive prognostic impact. The high expression of the metastasisassociated protein, S100A4 28 was also somewhat indicative of a higher metastatic rate among the high expressing group (13.41%) compared to the low expressing group (4.76%; p = 0.095; Fig. 4D ) but did not reach significance. We speculate that the prometastatic trends we observed in the case of both Daple-V1 and S100A4 did not reach significance because of insufficient patients in the cohort. Regardless, these findings are consistent with our recent findings that Daple-V2 is a potent tumor suppressor, whereas Daple-V1 triggers EMT and invasion 18, 22 .
Finally, we also found that patients with low Daple-V2 transcripts in their peripheral circulation had higher levels of other melanoma cell markers (Fig 5A-B ; Supplementary Table   S4 ; data from 7 ) , indicating that these patients may have higher numbers of circulating melanoma cells. Taken together, these findings suggest that Daple-V2 alone may serve as an effective prognostic marker in early stage melanoma.
Prognostic impact of Daple-V1 and Daple-V2 in patients with melanoma.
Because the frequency of metastatic progression was different for patients with high vs. low expression of transcripts for Daple-V1 or -V2 in the peripheral circulation at an early stage of disease (stage 0, I, II), we asked if levels of these transcripts can prognosticate progression free survival (PFS). Kaplan-Meier curves for high vs. low levels of expression of Daple-V1 and -V2 were plotted and compared between the 2 groups using the log rank test. In the case of Daple-V2, we found that PFS for patients with low expression was significantly reduced compared to patients with high expression (p=0.0139; Fig. 6A ). While in the case of Daple-V1, we found that patients with high expression tend to have shorter PFS compared to patients with low expression (p = 0.0833; Fig. 6B ). A similar pattern was found in PFS analysis of S100A4; patients with high expression tend to have shorter PFS compared to patients with low expression but this did not reach significance (p = 0.051; Fig. 6C ). These results indicate that Daple-V2, but not V1 is a favorable prognostic indicator of PFS. Next we asked if the prognostic impact of Daple-V1 and Daple-V2 are additive. When we compared PFS between the group with low Daple-V1-high Daple-V2 and the group with high Daple-V1-low Daple-V2, we found that patients with low Daple-V1-high Daple-V2 have a much higher PFS than the other group (p = 0.013; Fig. 6D-E) , indicating that Daple-V1 improves the prognostic value of Daple-V2.
Stratification of patients by accounting for the expression levels of both Daple-V1 and
Daple-V2 offers novel prognostic signatures.
To identify the most effective diagnostic algorithm that combines the prognostic impacts of both Daple isoforms, we explored if assessment of Daple-V1 among the patients with low Daple-V2 can improve the prognostic impact of Daple-V2. When we stratified patients with low Daple-V2 into two groups with high and low Daple-V1, we found that patients with high expression of Daple-V1 have shorter PFS than those with low expression of Daple-V1 (p = 0.0011; Fig. 7A ).
PFS among patients with low Daple-V2-high Daple-V1 expression was significantly lower than those with high Daple-V2 expression (p < 0.0001; Fig. 7B ).
We further evaluated the effect of Daple-V1 and -V2 on survival rates after adjustment for clinical covariates including age and tumor stage using Cox proportional hazard regression analysis (Cox analyses). We found that Daple-V2 can be an independent prognostic factor; PFS of patients with low Daple-V2 expression was significantly lower than those with high Daple-V2 (hazard ratio [HR] 9.1059; p = 0.00362; 95% confidence interval [CI] 1.1522 to 71.9672). Cox analyses also confirmed that Daple-V1 and Daple-V2 have additive prognostic value; PFS was significantly reduced when patients have high Daple-V1 and low Daple-V2 (HR 13.1368; p = 0.0172; CI 1.5792 to 109.2828). Although statistical significance was reached in each case, it is noteworthy that the 95% CIs are wide and further studies with larger cohort sizes are warranted.
Regardless, both log rank and Cox analyses are in agreement that Daple-V2 alone is a sufficient prognostic factor, and that risk stratification for tumor progression improves by the additive effect of Daple-V1 and Daple-V2. Risk was lowest when patients have low Daple-V1high Daple-V2 signature, and higher when patients have a high Daple-V1-low Daple-V2 signature.
Conclusions
The most important discovery we report here is a unique Daple/CCDC88C transcript signature, 'high Daple-V1 and low Daple-V2' in the peripheral blood of patients with early stage cutaneous melanoma that effectively stratifies patients at the highest risk for progression to metastatic disease. Daple-V1 triggers EMT via enhancement of non-canonical (β-catenin-independent) Wnt signals and suppresses canonical (β-catenin-dependent) Wnt signals 18 , whereas Daple-V2 serves primarily as a potent tumor suppressor 22 . Therefore, an increase in Daple-V1 at early stages in the peripheral blood (most likely from CMCs), suggests that non-canonical Wnt signals are likely enhanced and canonical Wnt signals are suppressed early during melanoma progression, a signature that has been previously described as a contributor to metastatic features of melanoma and poor survival [15] [16] [17] 31 . A decrease in the tumor suppressive isoform, Daple-V2 at late stages suggests that canonical Wnt signals are upregulated and may be necessary for the growth of metastatic lesions at distant sites. Overall, an increase in Daple-V1 and a decrease in Daple-V2 expression during disease progression is indicative of an overall permissive signaling program for melanoma progression, and this notion is consistent with the prognostic signature that emerged from this work as the most effective in predicting the risk for metastatic progression.
It is noteworthy that although lower Daple-V2 transcripts in the peripheral circulation were seen predominantly in patients with late stage disease, lower Daple-V2 transcripts in the early stage of the disease emerged as the strongest predictive profile in our study. This came as an unusual surprise to us because typically biomarkers representative of CTCs are elevated in circulation over background, not decreased. These findings raise the possibility that circulating melanocytes may be present in the peripheral circulation of healthy controls (hence, Daple-V2 transcript is detected in the circulation of normal healthy individuals), and that metastatic progression of melanoma may be associated with dissemination of different populations of CMCs that have low Daple-V2. In fact, this possibility is supported by prior studies that reported that melanocyte precursor cells -cells which express TYR and MITF transcripts, but not MLANA (or MIF) -may indeed circulate in healthy adults with benign nevus, are detected in human cord blood, [32] [33] [34] and during melanocytic differentiation into vein-like structures from pluripotent stem cells 35 . In patients with melanoma, a shift is noted in the landscape of the melanoma transcriptome, i.e., MLANA and MIF transcripts are elevated (but not TYR or MITF) 33 , leading some to speculate that the circulation of normal melanocytic precursors is inhibited in patients with melanomas, perhaps due to factors, e.g., cytokines released into the systemic circulation 33 . Based on these studies, and our own findings, we conclude that the entry of normal melanocytes and/or its precursors that have high Daple-V2 is inhibited in patients with melanoma, and instead, melanoma cells with lower Daple-V2 begin to enter the circulation. Because the burden of metastatic CMCs in the circulation increases with increasing clinical stage of disease 5 , the prognostic value of decreased Daple-V2 transcript that we observe in the early stage suggests that it may be a sensitive method to detect the changing landscape of melanocyte transcripts and serve as a surrogate marker for the overall load of metastatic CMCs.
Overall, we conclude that abundance of Daple transcripts (V1 and V2) in the peripheral blood of patients with melanoma may serve as a clinically useful early prognostic test for detecting sinister CMCs in the circulation. Because malignant melanoma is a disease that can be characterized by prolonged periods of tumor dormancy, which necessitates prolonged periods of follow-up, monitoring Daple transcripts in the peripheral circulation may serve as a relatively simple minimally-invasive test, either administered stand-alone, or in combination with other panels of melanoma markers. Further studies in larger cohorts are necessary before one can rigorously assess and realize the clinical usefulness of Daple in melanoma surveillance during follow-up, to detect tumor progression, to monitor response to therapy, and therefore to guide treatment plans.
Materials and Methods
Patient cohort and sample collection
All samples used in this study were previously analyzed as part of a prior study 7 Western Australia), while the aged-matched, healthy group were recruited from the general population. Detailed patient cohort information is listed in Table 1 . As reported previously 7 , 2.5 ml of whole blood was collected into a PAXgene Blood RNA Tube (PreAnalytiX, Hombrechtikon, Switzerland) containing RNA stabilizers. Total RNA was isolated using the PAXgene Blood RNA Kit (Qiagen, Hilden, Germany) and then reverse transcription was carried by Omniscript Reverse Transcriptase (Qiagen). Clinical data and post-blood collection follow-up was collected for all patients over 3 y and 9 mon.
Melanoma cell lines, RNA isolation, standard curve and quantitative PCR (qPCR)
Human melanoma cell line A375 (obtained from ATCC) were grown in Dubecco's modified Eagle's medium (DMEM; Gibco) media containing 10% fetal bovine serum (Hyclone) in T75 cm2 flask (Corning) until cells were ~70% confluent. Cells were then collected and total RNA was isolated using an RNeasy kit (QIAGEN) as per the manufacturers' protocol. First-strand cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen), followed by ribonuclease H treatment (Invitrogen) prior to performing quantitative real-time PCR. A standard curve, to quantify mRNA copy number, was constructed using larger PCR products (~500 bp) that included the target sequence used in qPCR. Reactions omitting reverse transcriptase were performed in each experiment as negative controls. Reactions were then run on a real-time
PCR system (ABI StepOnePlus; Applied Biosystems). Gene expression of Daple-V1, Daple-V2
and S100A4 was detected with Taqman assay (Invitrogen), and relative gene expression was determined by normalizing to GAPDH using Relative standard curve method. Primer and probe sequences are as listed in Supplementary Table 1 ( Table S1 ).
Analysis of melanoma-associated markers:
These analyses were carried out as described previously 7 . Briefly, total RNA (250 ng) was converted to cDNA (Omniscript Reverse Transcriptase, Qiagen), and included a no template control. qRT-PCR assays assessed the number of mRNA transcripts (level of expression) for three genes that have been previously shown to be associated with melanoma cells, and in some cases, indicative of stemness, i.e., MLANA, ABCB5 and MCAM. GAPDH was assessed as an internal loading control because its levels are not upregulated in melanoma tissues or cultured cells relative to normal samples 36 . These assays were carried out using SYBR GreenER qPCR SuperMix (Invitrogen) and 200 nmol L −1 of primer (Table S1) 
Statistical analyses
Statistical evaluation was performed using the GraphPad prism v5 software. Statistical significance of differences in marker expression among the patients with early vs. late stages of melanoma and normal healthy controls was analyzed using unpaired t-test. Optimal cut-off values for gene expression levels were derived by maximally selected log-rank statistics performed using R Software v2.15.0 37 . The relationship between high vs. low levels of gene expression and incidence of metastatic progression was investigated by Fisher's exact test. To assess the relationship between gene expression and patient's age, clinical stage of disease, Clark level, Breslow thickness and ulceration, we used parametric Pearson's correlation and nonparametric Spearman's correlation analyses. To estimate the correlation among the expression levels of various genes tested here, we used Correlation Matrix. To analyze the effect of high vs. low levels of gene expression and time-dependent survival probabilities we used Kaplan-Meier (KM) analyses. All statistical tests were performed two-sided, and p-values less than 0.05 were considered as statistically significant.
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All data generated or analyzed during this study are included in this published article (and its Supplementary Information files). The raw datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The TCGA datasets analyzed during the current study are available in the cBioPortal repository, -V1 alone (B) , Daple V1 and V2 combined (C), and S100A4 (D) in the peripheral blood. Bar graphs display the proportion of patients who progressed to metastasis (Y axis) in patients with low vs. high expression of indicated genes. (A) Compared to those with high Daple-V2 expression (n=55), those with low Daple-V2 (n = 90) expression displayed higher frequency of metastatic progression. (B) Compared to those with low Daple-V1 expression (n = 96), those with high Daple-V1 (n = 49) expression displayed higher frequency of metastatic progression. (C) Compared to those with low-V1-high-V2 signature (n = 28), those with high-V1-low-V2 (n = 22) expression displayed higher frequency of metastatic progression. (D) Compared to those with low S100A4 expression (n = 63), those with high S100A4 (n = 82) expression displayed higher frequency of metastatic progression. Optimal cut-off values for each gene expression were statistically derived (see detailed Methods) to divide patients into subgroups with low vs. high expression levels. Fisher exact test was used to compare the low vs. high subgroups. 
Figure 4. Frequency of progression to metastasis among patients stratified based on high vs. low levels of circulating transcripts of Daple-V2 alone (A), Daple
